It’s been more than 100 years since Nikolay Anitschkow discovered and confirmed ”The cholesterol hypothesis“ and the journey to understand cholesterol, hyperlipidemias and dyslipidemias has taken many twists and turns, but the all signs point to Moscow in 2020. Clinicians will not be disappointed.
Along the way, several crossroads and milestones have been marked: The connection between FH and coronary heart disease, the discovery of lipid lowering drugs, the Lipid Research Clinics Coronary Primary Prevention Trial, the discovery of statins, the Nobel prize for LDL-R function description, the “4S” trial when clinical lipidology “was stolen” from metabolism to cardiology 😊 On the other hand, as time passed, the successful story of the treatment of dyslipidemia fell into oblivion.
Nowadays, however, great progress in diagnostics (molecular as well as biochemical) and the treatment of dyslipidemias gives us cause for celebration again. The results from the PCSK9-I trials were positive and the development of new medications (new fibrates, siRNA molecules, APO CIII influencing drugs) has pulled lipids into the center of attention again.
All of these topics and more will be covered at the 2nd Anitschkow days in Moscow. The IAS conference will be mostly, but not exclusively, clinically oriented with recent research and knowledge to be summarized, with guidelines included, during the plenary sessions. Original papers will be discussed in smaller rooms and a poster session will be a great opportunity for young doctors and scientists to exchange knowledge.
Many internationally recognized speakers from almost all continents have promised to participate. We have every reason to believe that our partners from the industry will also actively participate.
The Russian Atherosclerosis Society anxiously await the opportunity to welcome delegates and to make your visit to Moscow an unforgettable one. Moscow is never more beautiful than at this time of year.
So, what are you waiting for? We look forward to seeing you at Anitschkow days in Moscow for a great showcase of science, medicine, new friendships and international cooperation.
Prof Richard Češka, MD, PhD, FACP, FEFIM
President of the Conference
Video Invitation by Richard Češka
IAS Secretary & President of the Conference
Video Invitation by Marat V. Ezhov
President of the Russian Atherosclerosis Society
Video Invitation by Peter Lansberg
About the IAS
The International Atherosclerosis Society (IAS) is a federation of 64 member organizations worldwide (representing 54 nations or regions) whose basic mission is to promote the scientific understanding of the etiology, prevention, and treatment of atherosclerosis. The IAS exists to coordinate the exchange of scientific information among the constituent societies, to foster research into the development of atherosclerosis, and to help translate this knowledge into improving the effectiveness of programs designed to prevent and treat this disease.